Form 4: Vertiv Executive Chairman's Spouse Sells $10.2M in Stock
Insider Transaction Report
David M. Cote, Executive Chairman of Vertiv Holdings Co, reported his spouse's sale of 40,000 Class A Common Stock shares totaling over $10.2 million.
Summary
- David M. Cote, Executive Chairman of Vertiv Holdings Co, reported the sale of 40,000 shares of Class A Common Stock by his spouse.
- The sales occurred on February 26, 2026, across multiple transactions with weighted average prices ranging from $250.23 to $258.26 per share.
- The total value of the shares sold exceeded $10.2 million.
- Following these transactions, the spouse's indirect beneficial ownership decreased to 22,258.03 shares.
- Cote also reported indirect beneficial ownership of various unexercised stock options held by grantor retained annuity trusts and a revocable trust, with various vesting and expiration dates extending to 2035.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a moderately negative signal due to the significant insider sale by the Executive Chairman's spouse, which could imply that the reporting person's family believes the stock is fully valued or that personal liquidity needs outweigh future appreciation potential.
Positives
- The sales were executed at relatively high prices, ranging from $250.23 to $258.26 per share, indicating a favorable market for the divestment.
- The reporting person continues to hold significant derivative securities (stock options) through trusts, indicating continued long-term interest in the company's performance.
Negatives
- An insider (spouse of the Executive Chairman) selling a substantial number of shares (40,000 shares) could be perceived negatively by the market, potentially signaling a belief that the stock price is near its peak or a lack of confidence.
- The total value of shares sold, over $10.2 million, represents a significant divestment from the company's equity by a closely related party.
Future Outlook
The filing primarily reports past and planned insider transactions and does not provide explicit forward-looking statements or guidance beyond the scheduled vesting dates for various stock options, which extend through March 2029.
Industry Context
StockSavvy.ai notes that insider sales, even by a spouse, are often scrutinized by the market as they can be interpreted as a signal regarding the company's future prospects or valuation. Vertiv operates in the critical digital infrastructure and continuity solutions sector, which has seen significant growth driven by data center expansion and AI adoption. While the sale is substantial, it's important to consider the context of the individual's overall holdings and potential personal financial planning, though the market may still view it as a bearish indicator.
Related Party Transactions
- The reported sales of Class A Common Stock were undertaken by the Reporting Person on behalf of the Reporting Person's spouse, constituting a related party transaction.
- The securities sold were held directly by the Reporting Person's spouse, and the Reporting Person maintains indirect beneficial ownership over various stock options held by a grantor retained annuity trust and a revocable trust.
Stakeholder Impact
- Shareholders: May interpret the significant insider sale as a negative signal, potentially leading to downward pressure on the stock price due to concerns about future performance or valuation.
- Management/Employees: No direct impact mentioned, but a large insider sale could subtly affect internal morale or perception of future prospects.
Key Dates
| Date | Description |
|---|---|
| 02/07/2020 | Grant date for 115,942 stock options with an exercise price of $12.05. |
| 02/04/2021 | Grant date for 115,942 stock options with an exercise price of $20.56. |
| 02/07/2021 | Vesting date for 28,985 stock options from the February 7, 2020 grant. |
| 03/03/2022 | Grant date for 86,956 stock options (held by trust) and 28,986 stock options (held by revocable trust), both with an exercise price of $11.5. |
| 02/04/2022 | Vesting date for 28,986 stock options from the February 4, 2021 grant. |
| 02/07/2022 | Vesting date for 28,986 stock options from the February 7, 2020 grant. |
| 03/07/2023 | Grant date for 25,000 stock options (held by trust) and 75,000 stock options (held by revocable trust), both with an exercise price of $15.84. |
| 02/04/2023 | Vesting date for 28,986 stock options from the February 4, 2021 grant. |
| 02/07/2023 | Vesting date for 28,985 stock options from the February 7, 2020 grant. |
| 03/03/2023 | Vesting date for 28,985 stock options from the March 3, 2022 grant. |
| 03/07/2024 | Grant date for 50,000 stock options (held by revocable trust) with an exercise price of $72.09. |
| 02/07/2024 | Vesting date for 28,986 stock options from the February 7, 2020 grant. |
| 03/03/2024 | Vesting date for 28,985 stock options from the March 3, 2022 grant. |
| 03/15/2024 | Vesting date for 25,000 stock options from the March 7, 2023 grant. |
| 03/07/2025 | Grant date for 46,012 stock options (held by revocable trust) with an exercise price of $85.04. |
| 02/04/2025 | Vesting date for 28,985 stock options from the February 4, 2021 grant. |
| 03/03/2025 | Vesting date for 28,986 stock options from the March 3, 2022 grant. |
| 03/15/2025 | Vesting date for 25,000 stock options from the March 7, 2023 grant and 12,500 stock options from the March 7, 2024 grant. |
| 02/26/2026 | Date of earliest transaction for the reported stock sales by the reporting person's spouse. |
| 03/02/2026 | Signature date of the Form 4 filing. |
| 03/03/2026 | Vesting date for 28,986 stock options from the March 3, 2022 grant. |
| 03/15/2026 | Vesting date for 25,000 stock options from the March 7, 2023 grant, 12,500 stock options from the March 7, 2024 grant, and 11,503 stock options from the March 7, 2025 grant. |
| 03/15/2027 | Vesting date for 25,000 stock options from the March 7, 2023 grant, 12,500 stock options from the March 7, 2024 grant, and 11,503 stock options from the March 7, 2025 grant. |
| 03/15/2028 | Vesting date for 12,500 stock options from the March 7, 2024 grant and 11,503 stock options from the March 7, 2025 grant. |
| 03/15/2029 | Vesting date for 11,503 stock options from the March 7, 2025 grant. |
| 02/07/2030 | Expiration date for 115,942 stock options granted on February 7, 2020. |
| 02/04/2031 | Expiration date for 115,942 stock options granted on February 4, 2021. |
| 03/03/2032 | Expiration date for 86,956 and 28,986 stock options granted on March 3, 2022. |
| 03/07/2033 | Expiration date for 25,000 and 75,000 stock options granted on March 7, 2023. |
| 03/07/2034 | Expiration date for 50,000 stock options granted on March 7, 2024. |
| 03/07/2035 | Expiration date for 46,012 stock options granted on March 7, 2025. |
Recommendation
sellThe significant insider sale by the spouse of the Executive Chairman, totaling over $10.2 million, suggests that a key insider is reducing exposure to the company's stock at current price levels. While personal financial planning can be a factor, such a large divestment often signals a belief that the stock may be overvalued or that future growth prospects are limited, making a 'sell' recommendation prudent for investors seeking to align with insider sentiment.
Keywords
Vertiv Holdings Co, VRT, insider trading, stock sale, Form 4, David M. Cote, executive chairman, beneficial ownership, stock options, equity sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.